Smoking before a PET scan floods the body with nicotine, which triggers a cascade of metabolic changes that can distort the images your doctor needs to read accurately. The most dramatic effect involves brown fat, a type of tissue that lights up intensely on the scan after nicotine exposure, potentially masking or mimicking disease. But brown fat is only one piece of the problem. Nicotine also alters blood flow, shifts glucose metabolism across multiple organs, and changes tracer behavior in the lungs and brain, all of which can compromise the diagnostic value of the scan.
How a PET Scan Actually Works
A PET scan typically uses a radioactive sugar called FDG (fluorodeoxyglucose). After injection, FDG travels through the bloodstream and gets taken up by cells in proportion to how much glucose they consume. Cancer cells, inflamed tissue, and highly active organs all gobble up more glucose than surrounding tissue, so they appear as bright spots on the scan. The radiologist reads those bright spots to locate tumors, assess how aggressively a cancer is behaving, or evaluate whether treatment is working.
The system depends on a clean signal. Anything that artificially increases glucose uptake in non-cancerous tissue creates noise that can obscure real disease or, worse, create bright spots that look like cancer but aren’t. Smoking does exactly this, in several ways at once.
The Brown Fat Problem
Brown adipose tissue, commonly called brown fat, is a specialized tissue whose job is to burn energy and generate heat. Unlike regular white fat, brown fat is packed with mitochondria and burns both fatty acids and glucose at a high rate when activated. In adults, brown fat clusters around the neck, shoulders, and along the spine. Under normal resting conditions it is relatively quiet and does not show up prominently on a PET scan.
Nicotine changes that picture dramatically. In a study using rats, nicotine injection increased FDG uptake in brown fat by nearly eight-fold compared to controls. That effect was stronger than ephedrine, which boosted brown fat uptake about four-fold. The mechanism runs through the sympathetic nervous system: nicotine triggers the release of norepinephrine, which binds to receptors on brown fat cells and ramps up glucose transport into the tissue. When researchers blocked those receptors with a beta-adrenergic antagonist beforehand, nicotine’s effect on brown fat was eliminated, confirming the pathway.1Journal of Nuclear Medicine. Effect of Nicotine and Ephedrine on the Accumulation of 18F-FDG in Brown Adipose Tissue
On a PET scan, activated brown fat appears as intense, symmetrical areas of FDG uptake across the neck and upper torso. These hotspots can be mistaken for lymph node metastases, especially in patients being scanned for head and neck cancers, lymphoma, or lung cancer. Even when a radiologist recognizes the pattern as brown fat, the bright signal can obscure nearby lymph nodes that actually do harbor disease. Either way, the scan becomes harder to interpret, and follow-up imaging or biopsy may be needed to sort things out.
Changes Across the Whole Body
Brown fat activation is the most visually striking artifact, but nicotine shifts glucose metabolism in organs throughout the body. A prospective study comparing chronic smokers with non-smokers on FDG-PET/CT found that smokers had significantly higher metabolic activity in visceral fat (the deep abdominal fat surrounding organs) and significantly lower metabolic activity in the liver and lumbar spinal bone marrow compared to non-smokers.2PubMed Central. A study of the feasibility of FDG-PET/CT to systematically detect and quantify differential metabolic effects of chronic tobacco use in organs of the whole body – a prospective pilot study
These shifts matter because the scan relies on normal tissue having a predictable background level of FDG uptake. When smoking alters that background, the contrast between healthy tissue and abnormal tissue changes. A tumor in the liver, for example, is easier to spot when the surrounding liver has its usual metabolic activity. If smoking has suppressed the liver’s baseline FDG uptake, a moderately active lesion may stand out more than it should, or the altered baseline could confuse quantitative measurements that oncologists use to track treatment response over time.
Blood Flow and Tracer Delivery
Nicotine is a vasoactive drug, meaning it directly changes the diameter of blood vessels. It constricts some vascular beds while altering the reactivity of vessel walls through both direct effects on smooth muscle and indirect effects on the endothelial lining.3PubMed Central. Nicotine and vascular dysfunction This matters for PET imaging because FDG reaches tissues through the blood. If smoking alters blood flow to a particular region right before or during the uptake period, the tracer may be delivered unevenly. Some areas get more FDG than they would normally receive, while others get less.
The lungs are especially vulnerable to this effect. Smoking causes acute changes in pulmonary blood flow patterns, and the combination of altered perfusion with direct inflammatory effects of smoke inhalation creates a messy picture on the scan. For patients being evaluated for lung cancer, where the whole point is distinguishing active tumor from normal lung tissue, any additional source of uneven FDG distribution makes the radiologist’s job harder.
What Smoking Does to Lung Cancer Scans Specifically
The relationship between smoking and lung cancer PET imaging goes beyond acute nicotine effects. A study of lung cancer patients found that the primary tumor’s maximum standardized uptake value (the number that reflects how intensely a lesion absorbs FDG) was significantly higher in smokers than in never-smokers. That difference was most pronounced in early-stage disease and in adenocarcinoma, one of the most common lung cancer subtypes. As cumulative smoking exposure increased, so did the primary tumor’s FDG uptake.4PubMed Central. Effects of cigarette smoking on metabolic activity of lung cancer on baseline 18F-FDG PET/CT
This finding has real implications for how scans are interpreted. A tumor that appears highly active on PET might genuinely be more aggressive, or the smoking history might be inflating the number. If a clinician uses that FDG uptake value to make decisions about treatment intensity, a smoking-inflated reading could lead to a different treatment plan than the tumor biology actually warrants. The study noted that in advanced-stage disease (stage III-IV), the difference between smokers and non-smokers disappeared, likely because aggressive late-stage tumors are already metabolically maxed out regardless of smoking status.
Separately, research has linked higher FDG uptake in the lungs of current and former smokers with emphysema progression over time, reflecting the chronic inflammatory process that smoking sustains in lung tissue.5ERJ Open Research. High 18F-fluorodeoxyglucose uptake in positron emission tomography–computed tomography is associated with emphysema progression This background inflammation adds another layer of non-specific FDG uptake that can complicate the interpretation of lung scans.
Brain PET Scans and Nicotine
When PET is used to study the brain, nicotine introduces a different set of problems. A study of awake resting tobacco smokers found that nicotine caused a small overall reduction in the brain’s global glucose metabolism, but specific regions showed relative increases. The thalamus, a relay center dense with nicotinic receptors, was among the regions most activated by nicotine. Parts of the frontal lobe, the posterior cingulate gyrus, and the visual cortex also showed increased relative activity, while the left insula and right inferior occipital gyrus showed decreases.6PubMed. Effects of nicotine on regional cerebral glucose metabolism in awake resting tobacco smokers
For a brain PET scan ordered to evaluate a neurological condition, detect early dementia, or locate a seizure focus, these regional shifts are a serious confound. A region that lights up because of nicotine could be confused with pathological hyperactivity, and a region that dims could mask a genuine abnormality. The effect is not subtle: some of the regional changes had high statistical confidence, and the thalamic activation in particular is a consistent finding given the density of nicotine-sensitive receptors there.
E-Cigarettes and Nicotine Replacement Products
The no-smoking rule before a PET scan is fundamentally about nicotine, not just combustible cigarettes. E-cigarettes deliver nicotine and would be expected to trigger the same sympathetic activation of brown fat, the same vascular changes, and the same shifts in organ-level glucose metabolism. A pilot study comparing e-cigarette users, cigarette smokers, and non-smoking controls found that e-cigarette users actually showed greater lung inflammation (measured with a different tracer targeting nitric oxide synthase) than either cigarette smokers or controls.7PubMed Central. Molecular Imaging of Pulmonary Inflammation in Users of Electronic and Combustible Cigarettes: A Pilot Study While that study used a non-FDG tracer, it underscores that e-cigarettes are not a harmless loophole when it comes to PET imaging.
Nicotine patches, gum, lozenges, and nasal sprays all deliver the same drug through different routes. The brown fat activation pathway runs through the bloodstream, so any form of nicotine that reaches your circulation can trigger it. Imaging centers typically ask patients to abstain from all nicotine products, not just cigarettes, for at least 24 hours before the scan. Some facilities extend that to 48 hours for heavy smokers, though practices vary.
This creates a genuine dilemma for patients who are heavy nicotine users. Nicotine withdrawal itself produces physiological changes, including stress hormone release and shifts in blood glucose, that could theoretically influence the scan. In practice, though, the interference from active nicotine exposure is far worse than any withdrawal effect, and the standard recommendation remains to stop all nicotine sources the day before the scan.
Cannabis and Other Inhaled Substances
Patients sometimes wonder whether cannabis needs to be avoided as well. Cannabis does not contain nicotine, so it will not trigger the brown fat activation pathway. However, smoked cannabis introduces its own complications. THC affects dopamine signaling in the brain, and a study using a dopamine-specific PET tracer found that smoking cannabis produced measurable transient changes in dopamine binding in the ventral striatum of every participant scanned.8PubMed Central. Assessment of Transient Dopamine Responses to Smoked Cannabis For brain PET studies looking at neurotransmitter systems, cannabis use before the scan would introduce obvious artifacts.
Even for standard FDG-PET scans of the body, smoking cannabis involves inhaling hot particulate matter that causes acute airway inflammation. That inflammation recruits immune cells to the lungs, and activated immune cells are avid glucose consumers that show up as diffuse FDG uptake in lung tissue. Most imaging centers recommend avoiding all inhaled substances before a PET scan, cannabis included, for this reason. Edible cannabis products do not carry the same lung inflammation risk, though THC’s systemic metabolic effects are less well-studied in the context of PET imaging.
The Fasting Connection
Smoking restrictions before a PET scan sit alongside another well-known preparation rule: fasting. Patients are typically told not to eat for four to six hours before the scan. Both instructions serve the same goal of ensuring FDG goes where the scan needs it to go, but through different mechanisms.
Eating raises blood sugar, which triggers insulin release. Insulin drives glucose (and FDG) into muscle and fat tissue throughout the body, creating a diffuse glow on the scan that drowns out the focal uptake that matters clinically. Smoking, by contrast, does not spike blood sugar in the same direct way, but nicotine stimulates the sympathetic nervous system to release stress hormones that can raise blood glucose modestly and alter insulin sensitivity. The combination of eating and smoking before a scan would compound both problems, which is why preparation instructions address them separately but with equal seriousness.
If your blood sugar is above the facility’s cutoff at the time of injection (usually around 150 to 200 mg/dL, depending on the center), the scan may be postponed. Smoking-related blood sugar fluctuations rarely push levels that high on their own, but in a patient with diabetes who also smoked recently, the effects can add up.
How Long Before the Scan Should You Stop
Most imaging centers ask for at least four to six hours without smoking, and many prefer 24 hours. The reasoning involves nicotine’s half-life, which is about one to two hours, meaning the drug itself clears the blood relatively quickly. But nicotine’s metabolite cotinine lingers for 15 to 20 hours, and the downstream sympathetic activation (particularly the priming of brown fat) does not switch off the instant nicotine leaves the bloodstream. Brown fat that has been activated may remain metabolically elevated for hours afterward.
The practical advice is straightforward: do not smoke, vape, or use any nicotine product from the evening before your scan. If you are a heavy smoker and your scan is scheduled for the afternoon, resist the urge to have a morning cigarette. Tell the technologist honestly if you did smoke, because that information helps the radiologist account for potential artifacts when reading the images. A scan performed after recent smoking is not necessarily useless, but the radiologist needs to know what they are looking at.
When Chronic Smoking Effects Cannot Be Separated From the Scan
There is an important distinction between acute nicotine effects (what happens in the hours after your last cigarette) and chronic smoking effects that are baked into your body’s baseline metabolism. The whole-body metabolic differences seen between chronic smokers and non-smokers, such as increased visceral fat activity and decreased liver and bone marrow metabolism, do not disappear after a 24-hour abstinence period.2PubMed Central. A study of the feasibility of FDG-PET/CT to systematically detect and quantify differential metabolic effects of chronic tobacco use in organs of the whole body – a prospective pilot study These are structural adaptations to years of smoking that persist even during abstinence.
Similarly, the elevated FDG uptake in the lungs of current and former smokers, linked to ongoing inflammatory processes and emphysema progression, represents chronic tissue changes rather than an acute response to the last cigarette.5ERJ Open Research. High 18F-fluorodeoxyglucose uptake in positron emission tomography–computed tomography is associated with emphysema progression Radiologists reading scans of long-term smokers are generally aware of these patterns and factor them into their interpretation. The pre-scan fasting from nicotine controls the acute, avoidable interference; the chronic effects are simply part of the clinical picture that needs to be read in context.
This is also why your smoking history matters for the imaging team even if you quit months or years ago. A former heavy smoker may still have altered baseline metabolism in several organ systems, and knowing that history helps the radiologist distinguish between changes attributable to past smoking and findings that warrant further investigation.
Hypoxia and Why Tumors in Smokers Can Behave Differently on PET
Smoking chronically reduces oxygen delivery to tissues, and tumors in smokers often exist in a more oxygen-starved (hypoxic) environment. Hypoxia itself changes how much FDG a tumor absorbs. Research on liver cancer cells showed that low oxygen conditions significantly increased the expression of glucose transporters on cell surfaces, which in turn increased both glycolysis rates and FDG uptake. Higher expression of these transporters correlated with more aggressive disease features, including larger tumors and worse survival.9PubMed. Hypoxia-induced modulation of glucose transporter expression impacts (18)F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma
This creates a feedback loop of sorts: smoking promotes tissue hypoxia, hypoxia upregulates glucose transporters, and more glucose transporters mean more FDG uptake on PET. A tumor in a smoker may look “hotter” on PET partly because the tumor is genuinely more aggressive in a hypoxic environment and partly because the hypoxia itself amplifies the tracer signal. Teasing apart these contributions is one of the ongoing challenges in interpreting PET scans in patients with significant smoking histories. It is a reminder that the effects of smoking on PET imaging extend well beyond the acute hit of nicotine from the last cigarette, reaching into the biology of the disease itself.